Disc Medicine Q1 net loss widens to $63.5M; bitopertin Phase 3 enrollment complete

Disc Medicine, Inc.

2026-Q1 EPS reported -$1.65

Net loss $63.5M vs $34.1M YoY; R&D expenses rose to $45.9M, SG&A to $23.6M.
Cash and securities $730.2M at March 31, 2026, funding operations into 2029.
Phase 3 APOLLO trial of bitopertin in EPP fully enrolled (N=183); topline data Q4 2026.
Updated Phase 2 DISC-0974 (MF anemia) data to be presented at ASCO June 2026 (N=61).
Phase 2 DISC-3405 (PV) and Phase 1b (SCD) data both expected in Q4 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Disc Medicine, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $63.5 million for the three months ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Net income: Net loss was $63.5 million for the three months ended March 31, 2026
Result: reported results

Exact text from the filing

On May 5, 2026, Disc Medicine, Inc. announced its financial results for the first quarter ended March 31, 2026 and provided a corporate update.

View on SEC.gov

Browse all earnings releases →

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-205187

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.